|
|
Article: FermaVir's Antiviral Portfolio Soon To Start Clinical Testing.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
About 18 months after it was founded to acquire and develop antiviral compounds, FermaVir Pharmaceuticals Inc. is one step closer to advancing its first candidate into the clinic.
The New York-based company, which filed a pre-investigational new drug application with the FDA in November, recently received a positive response from the agency to proceed with clinical development of FermaVir's CF-1743 compound for treating shingles, an infection caused by the Varicella zoster virus.
The FDA's response also included "advice on our preclinical plan," plus recommendations for drug development "all the way through Phase IIa," said ...